Document is current
Any future updates will be listed below
-
Authors
Alsaleh, K.
Al Zahwahry, H.
Bounedjar, A.
Oukkal, M.
Saadeddine, A.
Mahfouf, H.
Bouzid, K.
Bensalem, A.
Filali, T.
Abdel-Razeq, H.
Larbaoui, B.
Kandil, A.
Abulkhair, O.
Al Foheidi, M.
Ghosn, M.
Rasool, H.
Boussen, H.
Mezlini, A.
Haddaoui, A.
Ayari, J.
Al Ghamdi, M.
Errihani, H.
Abdel-Aziz, N.
Arafah, M.
Dabouz, F.
Bahadoor, M.
Kullab, S.
Nabholtz, J. M.
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03447132 at ClinicalTrials.govDocuments that mention this clinical trial
Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial
https://doi.org/10.1007/s00432-023-04588-3
- License Information
-
More Information
Article History
Received: 1 December 2022
Accepted: 11 January 2023
First Online: 21 January 2023
Declarations
:
: K. Alsaleh: Honoraria: Amgen, AstraZeneca, Novartis, Pfizer, Roche. Research grants: Pfizer and AstraZeneca. M. Oukkal: Advisory/Consultancy, Speaker Bureau/Expert testimony: Amgen; Roche, Novartis, Pfizer, Bayer. O. Abulkhair: Advisory Board: Pfizer, Roche, Lilly, Newbridge. Hikmat Abdel-Razeq: Honoraria: Hikma Pharmaceuticals, Sanofi, Roche. J.M. Nabholtz: Research grants: Pfizer, AstraZeneca, Genomic Health, MSD. Honoraria: Amgen, AstraZeneca, MSD, Novartis, Pfizer, Roche. H. Al Zahwahry, A. Bounedjar, A. Saadeddine, H. Mahfouf, K. Bouzid, A. Bensalem, T. Fillali, B. Larbaoui, A. Kandil, H. Boussen, M. Al Foheidi, Jihen Ayari, M. Al Ghamdi, H. Errihani, M. Ghosn, N. Abdel-Aziz, M. Arafah, F. Dabouz, M. Bahadoor, S. Kullab: None declared.
Free to read: This content has been made available to all.
